SLAOT 2016

SLAOT 2016
Punta Cana, República Dominicana

sábado, 5 de abril de 2014

FDA approves apremilast to treat adults with psoriatic arthritis

http://www.healio.com/rheumatology/psoriatic-arthritis/news/online/%7B31a0e42c-d95c-49c9-8a20-00e4a8d7b45b%7D/fda-approves-apremilast-to-treat-adults-with-psoriatic-arthritis


FDA approves apremilast to treat adults with psoriatic arthritis

  • March 21, 2014
The FDA announced today it has approved apremilast to treat adults with active psoriatic arthritis.
Apremilast (Otezla, Celgene Corp.) is a phosphodiesterase-4 inhibitor. Approval was based on three clinical trials studying 1,493 patients with active psoriatic arthritis (PsA), according to an FDA news release. Patients treated with apremilast displayed improvements in disease signs and symptoms, including tender and swollen joints and physical function, when compared with placebo-treated patients.

No hay comentarios:

Publicar un comentario